Combimatrix Corp (CBMX) 1.83 $CBMX
CombiMatrix raises ~$5M in direct offering
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 11:56AM CST
CBMX: 1.83 (-0.16)
CombiMatrix Announces $4.9 Million Registered Direct Offering
GlobeNewswire - Fri Feb 13, 11:13AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, announced today that it has entered into an agreement to issue securities in a registered direct offering to accredited institutional pre-existing investors that will result in gross proceeds to the Company totaling $4.9 million.
CBMX: 1.83 (-0.16)
Massachusetts fertility lab picks up CombiMatrix test
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 9:15AM CST
CBMX: 1.83 (-0.16)
CombiMatrix's Miscarriage Analysis Test Now Offered by ReproSource, Inc.
GlobeNewswire - Thu Jan 22, 7:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced that ReproSource, Inc., a nationally-recognized laboratory dedicated to fertility specialists and the patients they serve, is now offering CombiMatrix's chromosomal microarray analysis (CMA) testing for miscarriage analysis. ReproSource, based just outside of Boston, Massachusetts, is an international clinical reference laboratory providing specialized diagnostic services for unexplained infertility, recurrent pregnancy loss and premature ovarian failure.
CBMX: 1.83 (-0.16)
CombiMatrix Names Karen Warner, RN, Vice President of Reimbursement
GlobeNewswire - Tue Jan 20, 7:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced the appointment of Karen Warner, RN, as Vice President of Payer Access and Reimbursement. Ms. Warner joined on January 19, 2015 and will be responsible for managed care, payer access, and reimbursement.
CBMX: 1.83 (-0.16)
CombiMatrix to Present at the 8th Annual OneMedForum Conference
GlobeNewswire - Wed Jan 07, 7:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced that Mark McDonough, CEO of CombiMatrix, will be presenting at the upcoming 8 Annual OneMedForum Conference in San Francisco. Mr. McDonough's presentation will begin at 10:10 a.m. PST on Monday, January 12, at the San Francisco Marriott Marquis hotel.
CBMX: 1.83 (-0.16)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 11:45AM CST
SD: 2.09 (+0.14), FRO: 2.96 (+0.07), EXXI: 4.00 (+0.42), HGG: 6.78 (+0.34), QADA: 20.36 (+0.14), CBMX: 1.83 (-0.16), CHOP: 0.87 (-0.01), CLDN: 16.45 (-0.05), MOC: 2.24 (+0.02), NDRM: 10.76 (+0.22), CALI: 1.35 (+0.06), GDP: 3.58 (+0.29), TNXP: 5.78 (-0.02), ICEL: 5.27 (+0.02), NERV: 4.68 (+0.09), CYTR: 2.96 (+0.23), BBLU: 1.26 (+0.09), ATHX: 2.12 (unch), PEIX: 9.82 (+0.15), PGN: 2.88 (-0.07)
Court rules in favor of CombiMatrix in insurance fraud case
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 9:01AM CST
CBMX: 1.83 (-0.16)
Superior Court Issues Tentative Ruling and Proposed Statement of Decision in Favor of CombiMatrix
GlobeNewswire - Tue Jan 06, 5:07AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced that the Superior Court of the State of California, County of Orange (the "Court"
, has issued a tentative ruling and proposed statement of decision (the "Proposed Statement of Decision" in the matter of the People of the State of California and Relator Michael Strathmann ("Plaintiff" vs. Acacia Research Corporation, CombiMatrix Corporation and Amit Kumar ("Defendants" . In its 27-page Proposed Statement of Decision, the Court has tentatively ruled in favor of the Defendants and against all claims of the Plaintiff. Specifically, the Court determined that Defendants had no fraudulent intent when they pursued insurance benefits under the National Union D&O Policy over a decade ago. Each party in this case now has up to fifteen days to file any objections it may have. The Court then has approximately 60 days to consider the objections and to hear additional arguments before the Court issues its final ruling and judgment.
ACTG: 13.13 (+0.04), CBMX: 1.83 (-0.16)
CombiMatrix Launches Targeted Array for Prenatal Analysis
GlobeNewswire - Tue Dec 16, 7:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced the launch of its Targeted Array for Prenatal Analysis. This new test offers the superior diagnostic power of microarray analysis for the detection of clinically relevant microdeletion and microduplication disorders, while minimizing the risk of identifying a variant of uncertain significance (VOUS) on chorionic villus sampling (CVS) and amniocentesis samples.
CBMX: 1.83 (-0.16)
CombiMatrix Promotes Karine Hovanes, Ph.D., to Vice President of Scientific Advancement and Laboratory Director, and Trilochan Sahoo, M.D., to Vice President of Clinical Affairs and Director of Cytogenetics
GlobeNewswire - Wed Nov 19, 7:07AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced the promotions of Karine Hovanes, Ph.D., to Vice President of Scientific Advancement and Laboratory Director and Trilochan Sahoo, M.D., to Vice President of Clinical Affairs and Director of Cytogenetics. The new medical leadership team will assume the responsibilities of R. Weslie Tyson, M.D., Chief Medical Officer of CombiMatrix, who will retire on December 12, 2014.
CBMX: 1.83 (-0.16)
CombiMatrix Enters IVF Market With Launch of CombiPGS(TM)
GlobeNewswire - Tue Nov 18, 7:40AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced the launch of CombiPGS(TM), a preimplantation genetic screening (PGS) test for women undergoing in vitro fertilization (IVF). CombiPGS allows couples to screen embryos for chromosomal abnormalities prior to implantation of the embryo in order to maximize the chance of successful implantation and pregnancy progression and to decrease the likelihood of a miscarriage.
CBMX: 1.83 (-0.16)
CombiMatrix's (CBMX) CEO Mark McDonough on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:51PM CST
CBMX: 1.83 (-0.16)
CombiMatrix beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:31PM CST
CBMX: 1.83 (-0.16)
CombiMatrix Reports Third Quarter 2014 Financial and Operating Results
GlobeNewswire - Tue Nov 04, 3:05PM CST
- Reports Record Revenue, Cash Reimbursement and Test Volumes -
CBMX: 1.83 (-0.16)
CombiMatrix reports November 4
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:48PM CDT
CBMX: 1.83 (-0.16)
CombiMatrix Corporation to Release Third Quarter Financial Results on November 4, 2014
GlobeNewswire - Tue Oct 28, 3:05PM CDT
CombiMatrix Corporation (Nasdaq:CBMX) announced today that it will release its third quarter 2014 financial results on Tuesday, November 4, 2014. Results will be released after the close of trading on that day.
CBMX: 1.83 (-0.16)
Data to be Presented at ASHG 2014 Show That Miscarriage Analysis by Chromosomal Microarray Yields a Successful Result in More Than 85% of Cases
GlobeNewswire - Tue Oct 14, 7:08AM CDT
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced data from a comprehensive, multi-year analysis of products of conception (POC) testing by chromosomal microarray analysis (CMA) showing that CMA yields a successful result in more than 85% of cases. Trilochan Sahoo, M.D., Director of cytogenetics at CombiMatrix, will present results at the American Society of Human Genetics (ASHG)'s 64 Annual Meeting on Monday, October 20, 2014 in San Diego, California.
CBMX: 1.83 (-0.16)
CombiMatrix Reports Preliminary Growth in Prenatal Microarray Testing Volumes of 71% and 64% for the Third Quarter and Year-to-Date, Respectively
GlobeNewswire - Tue Oct 07, 7:00AM CDT
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced that it expects to report record volumes of prenatal testing in the third quarter and nine months ended September 30, 2014. Preliminary growth rates of 71 percent and 64 percent are estimated for billable prenatal tests in the third quarter and year-to-date periods, respectively, compared to the comparable periods in 2013. The Company believes the growth rate in prenatal testing, which includes both prenatal and miscarriage testing, is the result of the Company's strategic shift to focus on its prenatal molecular diagnostics testing markets, where the Company believes that chromosomal microarray analysis is becoming the standard of care.
CBMX: 1.83 (-0.16)
CBMX, EGFEY, Removed From Naked Short Lists Today
M2 - Thu Sep 11, 9:03AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. CombiMatrix Corp (NASDAQ:CBMX), EFG EUROBANK ERGASI-UNSP ADR (OTC:EGFEY). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
CBMX: 1.83 (-0.16)
CombiMatrix raises ~$5M in direct offering
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 11:56AM CST
CBMX: 1.83 (-0.16)
CombiMatrix Announces $4.9 Million Registered Direct Offering
GlobeNewswire - Fri Feb 13, 11:13AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, announced today that it has entered into an agreement to issue securities in a registered direct offering to accredited institutional pre-existing investors that will result in gross proceeds to the Company totaling $4.9 million.
CBMX: 1.83 (-0.16)
Massachusetts fertility lab picks up CombiMatrix test
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 9:15AM CST
CBMX: 1.83 (-0.16)
CombiMatrix's Miscarriage Analysis Test Now Offered by ReproSource, Inc.
GlobeNewswire - Thu Jan 22, 7:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced that ReproSource, Inc., a nationally-recognized laboratory dedicated to fertility specialists and the patients they serve, is now offering CombiMatrix's chromosomal microarray analysis (CMA) testing for miscarriage analysis. ReproSource, based just outside of Boston, Massachusetts, is an international clinical reference laboratory providing specialized diagnostic services for unexplained infertility, recurrent pregnancy loss and premature ovarian failure.
CBMX: 1.83 (-0.16)
CombiMatrix Names Karen Warner, RN, Vice President of Reimbursement
GlobeNewswire - Tue Jan 20, 7:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced the appointment of Karen Warner, RN, as Vice President of Payer Access and Reimbursement. Ms. Warner joined on January 19, 2015 and will be responsible for managed care, payer access, and reimbursement.
CBMX: 1.83 (-0.16)
CombiMatrix to Present at the 8th Annual OneMedForum Conference
GlobeNewswire - Wed Jan 07, 7:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced that Mark McDonough, CEO of CombiMatrix, will be presenting at the upcoming 8 Annual OneMedForum Conference in San Francisco. Mr. McDonough's presentation will begin at 10:10 a.m. PST on Monday, January 12, at the San Francisco Marriott Marquis hotel.
CBMX: 1.83 (-0.16)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 11:45AM CST
SD: 2.09 (+0.14), FRO: 2.96 (+0.07), EXXI: 4.00 (+0.42), HGG: 6.78 (+0.34), QADA: 20.36 (+0.14), CBMX: 1.83 (-0.16), CHOP: 0.87 (-0.01), CLDN: 16.45 (-0.05), MOC: 2.24 (+0.02), NDRM: 10.76 (+0.22), CALI: 1.35 (+0.06), GDP: 3.58 (+0.29), TNXP: 5.78 (-0.02), ICEL: 5.27 (+0.02), NERV: 4.68 (+0.09), CYTR: 2.96 (+0.23), BBLU: 1.26 (+0.09), ATHX: 2.12 (unch), PEIX: 9.82 (+0.15), PGN: 2.88 (-0.07)
Court rules in favor of CombiMatrix in insurance fraud case
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 9:01AM CST
CBMX: 1.83 (-0.16)
Superior Court Issues Tentative Ruling and Proposed Statement of Decision in Favor of CombiMatrix
GlobeNewswire - Tue Jan 06, 5:07AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced that the Superior Court of the State of California, County of Orange (the "Court"
, has issued a tentative ruling and proposed statement of decision (the "Proposed Statement of Decision" in the matter of the People of the State of California and Relator Michael Strathmann ("Plaintiff" vs. Acacia Research Corporation, CombiMatrix Corporation and Amit Kumar ("Defendants" . In its 27-page Proposed Statement of Decision, the Court has tentatively ruled in favor of the Defendants and against all claims of the Plaintiff. Specifically, the Court determined that Defendants had no fraudulent intent when they pursued insurance benefits under the National Union D&O Policy over a decade ago. Each party in this case now has up to fifteen days to file any objections it may have. The Court then has approximately 60 days to consider the objections and to hear additional arguments before the Court issues its final ruling and judgment. ACTG: 13.13 (+0.04), CBMX: 1.83 (-0.16)
CombiMatrix Launches Targeted Array for Prenatal Analysis
GlobeNewswire - Tue Dec 16, 7:00AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced the launch of its Targeted Array for Prenatal Analysis. This new test offers the superior diagnostic power of microarray analysis for the detection of clinically relevant microdeletion and microduplication disorders, while minimizing the risk of identifying a variant of uncertain significance (VOUS) on chorionic villus sampling (CVS) and amniocentesis samples.
CBMX: 1.83 (-0.16)
CombiMatrix Promotes Karine Hovanes, Ph.D., to Vice President of Scientific Advancement and Laboratory Director, and Trilochan Sahoo, M.D., to Vice President of Clinical Affairs and Director of Cytogenetics
GlobeNewswire - Wed Nov 19, 7:07AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced the promotions of Karine Hovanes, Ph.D., to Vice President of Scientific Advancement and Laboratory Director and Trilochan Sahoo, M.D., to Vice President of Clinical Affairs and Director of Cytogenetics. The new medical leadership team will assume the responsibilities of R. Weslie Tyson, M.D., Chief Medical Officer of CombiMatrix, who will retire on December 12, 2014.
CBMX: 1.83 (-0.16)
CombiMatrix Enters IVF Market With Launch of CombiPGS(TM)
GlobeNewswire - Tue Nov 18, 7:40AM CST
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced the launch of CombiPGS(TM), a preimplantation genetic screening (PGS) test for women undergoing in vitro fertilization (IVF). CombiPGS allows couples to screen embryos for chromosomal abnormalities prior to implantation of the embryo in order to maximize the chance of successful implantation and pregnancy progression and to decrease the likelihood of a miscarriage.
CBMX: 1.83 (-0.16)
CombiMatrix's (CBMX) CEO Mark McDonough on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:51PM CST
CBMX: 1.83 (-0.16)
CombiMatrix beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:31PM CST
CBMX: 1.83 (-0.16)
CombiMatrix Reports Third Quarter 2014 Financial and Operating Results
GlobeNewswire - Tue Nov 04, 3:05PM CST
- Reports Record Revenue, Cash Reimbursement and Test Volumes -
CBMX: 1.83 (-0.16)
CombiMatrix reports November 4
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:48PM CDT
CBMX: 1.83 (-0.16)
CombiMatrix Corporation to Release Third Quarter Financial Results on November 4, 2014
GlobeNewswire - Tue Oct 28, 3:05PM CDT
CombiMatrix Corporation (Nasdaq:CBMX) announced today that it will release its third quarter 2014 financial results on Tuesday, November 4, 2014. Results will be released after the close of trading on that day.
CBMX: 1.83 (-0.16)
Data to be Presented at ASHG 2014 Show That Miscarriage Analysis by Chromosomal Microarray Yields a Successful Result in More Than 85% of Cases
GlobeNewswire - Tue Oct 14, 7:08AM CDT
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced data from a comprehensive, multi-year analysis of products of conception (POC) testing by chromosomal microarray analysis (CMA) showing that CMA yields a successful result in more than 85% of cases. Trilochan Sahoo, M.D., Director of cytogenetics at CombiMatrix, will present results at the American Society of Human Genetics (ASHG)'s 64 Annual Meeting on Monday, October 20, 2014 in San Diego, California.
CBMX: 1.83 (-0.16)
CombiMatrix Reports Preliminary Growth in Prenatal Microarray Testing Volumes of 71% and 64% for the Third Quarter and Year-to-Date, Respectively
GlobeNewswire - Tue Oct 07, 7:00AM CDT
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced that it expects to report record volumes of prenatal testing in the third quarter and nine months ended September 30, 2014. Preliminary growth rates of 71 percent and 64 percent are estimated for billable prenatal tests in the third quarter and year-to-date periods, respectively, compared to the comparable periods in 2013. The Company believes the growth rate in prenatal testing, which includes both prenatal and miscarriage testing, is the result of the Company's strategic shift to focus on its prenatal molecular diagnostics testing markets, where the Company believes that chromosomal microarray analysis is becoming the standard of care.
CBMX: 1.83 (-0.16)
CBMX, EGFEY, Removed From Naked Short Lists Today
M2 - Thu Sep 11, 9:03AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. CombiMatrix Corp (NASDAQ:CBMX), EFG EUROBANK ERGASI-UNSP ADR (OTC:EGFEY). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
CBMX: 1.83 (-0.16)
